Prothrombin

Prothrombin is a protein found in your blood. It's like a key that helps your blood clot when you get a cut. Your body makes it, and it's essential for stopping bleeding. If you don't have enough prothrombin, it can make it harder for your blood to clot properly.

Brand names:Factor II
Medication

What people taking Prothrombin report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Prothrombin

What It's For

Prothrombin, also called factor II, is one of the proteins the blood needs to form a clot. The liver makes it with the help of vitamin K. As a medicine, prothrombin is not given on its own in the US. It is one ingredient of prothrombin complex concentrate (PCC), a hospital treatment made from donated human plasma that replaces several clotting proteins at once. The four-factor concentrates Kcentra and Balfaxar contain prothrombin together with clotting factors VII, IX and X and two natural anticlotting proteins, proteins C and S. Kcentra is approved to quickly reverse the effect of warfarin, a blood thinner that works by blocking vitamin K, in adults who have major bleeding or need urgent surgery or another urgent procedure. Balfaxar is approved for the urgent surgery or procedure situation only. Some guidelines also suggest four-factor PCC, outside its approved label, as one option for life-threatening bleeding in people taking apixaban or rivaroxaban, newer blood thinners that block clotting factor X. In the rare inherited condition congenital prothrombin deficiency, there is no dedicated prothrombin product, so PCC or plasma is used to treat or prevent bleeding. A related product, Profilnine, also contains prothrombin but is approved only for hemophilia B.

How It Works

Clotting works like a relay. When a blood vessel is injured, a series of clotting factors switch on one after another. Near the end of that chain, activated factor X converts prothrombin into thrombin, the enzyme that turns the blood protein fibrinogen into the strands of fibrin that hold a clot together. Warfarin blocks vitamin K, which the liver needs to make working prothrombin and factors VII, IX and X, so a person taking it has low levels of all four. PCC puts those factors straight back into the bloodstream, restoring clotting ability far faster than the liver can rebuild them. The concentrate also contains proteins C and S, the body's own natural brakes on clotting.

Dosage & Administration

PCC is given only in a hospital or similar setting, as an infusion into a vein after the powder is mixed with sterile water. For warfarin reversal, the dose is worked out from body weight and from the INR (international normalized ratio), a blood test that shows how long the blood takes to clot. The higher the INR, the more slowly the blood clots, so a higher starting INR calls for a larger dose. The INR is checked just before the infusion and again during and after it. Vitamin K is given at the same time. The concentrate's effect fades, and vitamin K lets the liver go back to making its own working clotting factors so the correction lasts. A second dose of Kcentra has not been shown to be safe or effective and is not recommended. For congenital prothrombin deficiency, a hematologist (blood specialist) sets the plan. Prothrombin lasts only about three days in the blood, so treatment may need repeating around a bleed or an operation.

Side Effects

In clinical trials, the most common side effects after Kcentra were headache, nausea or vomiting, low blood pressure and anemia (a low red blood cell count). The most important serious risk is a blood clot, which can cause a stroke, heart attack, pulmonary embolism (a clot in the lungs) or deep vein thrombosis (a clot in a deep leg vein). Tell the hospital team immediately, or call 911 if you have already gone home, about new swelling or pain in a leg or the abdomen, chest pain or pressure, shortness of breath, sudden numbness or weakness, confusion, or trouble with vision or speech. Allergic reactions can happen during or after the infusion. Hives, a rash, chest tightness, wheezing or feeling faint should be reported to the nurse right away so the infusion can be stopped and the reaction treated.

Interactions & Warnings

Kcentra and Balfaxar carry a boxed warning, the most prominent warning the US Food and Drug Administration (FDA) requires, about blood clots in arteries and veins, including fatal ones. People who take warfarin usually do so because they are already prone to clots, and reversing it removes that protection for a time. Kcentra was not studied in people who had a clot, heart attack, stroke, transient ischemic attack (a brief stroke-like episode), unstable angina or severe circulation problems in the legs within the previous 3 months, and it may not be suitable for them. The team weighs this against the danger of the bleeding or of delaying surgery. Kcentra is not given to people with heparin-induced thrombocytopenia, a serious immune reaction to the blood thinner heparin, because it contains a small amount of heparin. It is also not used in disseminated intravascular coagulation, a condition in which clotting switches on throughout the body, or after a previous severe allergic reaction to the product. Because PCC is made from human plasma, it carries a small risk of passing on infections. Donors are screened and the product goes through virus-reducing steps, and no infection has been shown to come from Kcentra since a virus-filtering step was added in 1996. There is little information about use in pregnancy, so it is given during pregnancy only when clearly needed.

What to Expect

PCC works quickly. In trials, Kcentra brought the INR down to 1.3 or lower within 30 minutes in most people. A corrected INR does not by itself guarantee that bleeding stops, so the team also treats the source of the bleeding, watches the overall response and keeps checking for signs of a clot during and after the infusion. Once the emergency or procedure is over, the team decides when to restart a blood thinner. That decision balances the chance of the bleeding returning against the chance of a clot, and the timing differs from person to person. Someone who received PCC to reverse warfarin should leave with a plan for whether and when to restart it and for the INR checks that follow. Congenital prothrombin deficiency is very rare, affecting roughly 1 in 2 million people. How much a person bleeds depends largely on how much working prothrombin they make: people with very low levels tend to bleed more and earlier in life, while milder cases may only show up after an injury or on blood tests before surgery. Treatment is usually given around bleeds and operations, and preventive treatment has been suggested for children with severe, life-threatening bleeding. Evidence comes mostly from small reports.

Questions to Ask Your Doctor

  1. 1.Why is prothrombin complex concentrate being used in my situation rather than plasma or another reversal medicine?
  2. 2.Does my history of blood clots, heart attack or stroke change the risks of this treatment for me?
  3. 3.When will I restart my blood thinner, and what will tell us it is safe to do so?
  4. 4.What signs of a clot or of renewed bleeding should I watch for after I leave the hospital?
  5. 5.If I have congenital prothrombin deficiency, what should happen before surgery or dental work, and who coordinates it?

Last reviewed • Oct 2026

Educational content, not medical advice.